AGED Diagnostics Liver Disease Assessment

Launched by ACTIVE GENOMES EXPRESSED DIAGNOSTICS, CORP · Apr 1, 2024

Keywords

ClinConnect Summary

The AGED Diagnostics Liver Disease Assessment trial is researching how to better identify different types of liver diseases using blood tests. Specifically, it aims to find ways to tell the difference between a condition called NASH (a type of fatty liver disease with inflammation) and other liver issues, as well as to understand the stage of fibrosis (scarring of the liver) a person may have. To do this, researchers will analyze blood samples from many people to validate specific markers that indicate these conditions.

To participate in this trial, you may be eligible if you have had a liver biopsy in the last couple of years and are either healthy or have certain conditions like metabolic syndrome or liver disease. However, individuals with known chronic liver diseases (other than NAFLD), those who drink alcohol excessively, or those who are pregnant cannot participate. If you join, you can expect to provide blood samples, and your health information will be used to help improve tests for liver diseases in the future. The trial is still in the early stages and is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant with liver biopsy over the past 1-2 years are permissible for study inclusion.
• • Participant is considered to be a "Healthy Subject" relative to any form of liver disease OR
• • Participant is suspected of having one of the following diagnoses: metabolic syndrome, NAFLD, fibrosis/cirrhosis, cardiovascular disease, chronic kidney disease.
• Exclusion Criteria:
• • Participant is known to have HIV, Hepatitis B or Hepatitis C
• • Participant has any other known form of chronic liver disease (aside from NAFLD/liver fibrosis)
• • Participant has excess alcohol intake, excess alcohol is defined as participants that exceed an average 20g of alcohol daily for females (140g weekly intake) and average 30g of alcohol daily for males (210g weekly intake)
• • Participant has had a bone marrow transplant at any time
• • Participant is on anti-coagulation or anti-platelet therapy
• • Participant is known to be pregnant
• • Participant is unable to provide informed consent